Israel Englander Millennium Management
Israel “Izzy” Englander is the founder of Millennium Management, one of the world’s largest multi-strategy hedge fund platforms. Millennium allocates capital across hundreds of independent teams rather than a single house view, with rigorous risk controls at the platform level. Englander’s model has been highly influential in the rise of pod-shop multi-manager structures across the industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$643M |
| 2 |
AT&T
T
|
+$311M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$306M |
| 4 |
Microsoft
MSFT
|
+$292M |
| 5 |
Ametek
AME
|
+$215M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$887M |
| 2 |
Apple
AAPL
|
+$694M |
| 3 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$616M |
| 4 |
Amazon
AMZN
|
+$596M |
| 5 |
Linde
LIN
|
+$531M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 58.05% |
| 2 | Technology | 7.69% |
| 3 | Financials | 6.83% |
| 4 | Healthcare | 6.42% |
| 5 | Industrials | 4.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HOFV
4001
DELISTED
Hall of Fame Resort & Entertainment Co
HOFV
| $1.81M | ﹤0.01% |
+30,994
| New | +$2.08M |
|
4002
Immunovant
IMVT
$8.51B
| $1.81M | ﹤0.01% |
207,926
-288,497
| -58% | -$2.6M |
|
4003
CALL
Cardinal Health
CAH
$54.6B
| $1.8M | ﹤0.01% |
36,500
-139,500
| -79% | -$7.57M |
|
4004
CorVel
CRVL
$3.5B
| $1.8M | ﹤0.01% |
29,076
+3,789
| +15% | +$197K |
|
4005
Sera Prognostics
SERA
$81.7M
| $1.8M | ﹤0.01% |
+162,245
| New | +$1.68M |
|
|
SGMO
4006
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $1.8M | ﹤0.01% |
199,619
+41,768
| +26% | +$413K |
|
|
ATMR.U
4007
DELISTED
Altimar Acquisition Corp II Units
ATMR.U
| $1.8M | ﹤0.01% |
181,000
-1,058,617
| -85% | -$10.7M |
|
|
EVBN
4008
DELISTED
Evans Bancorp Inc
EVBN
| $1.79M | ﹤0.01% |
46,865
-27,041
| -37% | -$1.04M |
|
|
JNCE
4009
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $1.79M | ﹤0.01% |
241,225
-217,091
| -47% | -$1.34M |
|
|
FIV
4010
DELISTED
First Trust Senior Floating Rate 2022 Target Term Fund Common Shares of Beneficial Interest
FIV
| $1.79M | ﹤0.01% |
185,619
| – | – |
|
4011
Alaunos Therapeutics
TCRT
$4.08M
| $1.78M | ﹤0.01% |
6,539
+4,078
| +166% | +$1.25M |
|
4012
Green Dot
GDOT
$760M
| $1.78M | ﹤0.01% |
35,422
-4,149
| -10% | -$200K |
|
4013
OneWater Marine
ONEW
$199M
| $1.78M | ﹤0.01% |
44,349
+1,752
| +4% | +$73.5K |
|
4014
Caribou Biosciences
CRBU
$174M
| $1.78M | ﹤0.01% |
+74,674
| New | +$1.83M |
|
4015
Sturm, Ruger & Co
RGR
$595M
| $1.78M | ﹤0.01% |
24,150
+20,100
| +496% | +$1.56M |
|
|
EVLO
4016
PUT
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| $1.78M | ﹤0.01% |
+12,645
| New | +$2.51M |
|
|
BOAS
4017
DELISTED
BOA Acquisition Corp.
BOAS
| $1.78M | ﹤0.01% |
183,357
-465,900
| -72% | -$4.51M |
|
|
ONT
4018
Onterris Inc
ONT
$598M
| $1.78M | ﹤0.01% |
28,811
+11,885
| +70% | +$622K |
|
4019
CALL
State Street
STT
$53.1B
| $1.78M | ﹤0.01% |
+21,000
| New | +$1.83M |
|
|
SY
4020
So-Young International
SY
$241M
| $1.78M | ﹤0.01% |
417,490
-261,094
| -38% | -$1.7M |
|
4021
Marathon Digital Holdings
MARA
$4.12B
| $1.77M | ﹤0.01% |
+56,164
| New | +$1.83M |
|
|
PMBC
4022
DELISTED
Pacific Mercantile Bancorp
PMBC
| $1.77M | ﹤0.01% |
192,412
+48,645
| +34% | +$421K |
|
4023
CALL
SL Green Realty
SLG
$4.08B
| $1.77M | ﹤0.01% |
+25,000
| New | +$1.83M |
|
4024
CALL
Iron Mountain
IRM
$35B
| $1.77M | ﹤0.01% |
+40,700
| New | +$1.83M |
|
4025
Nautilus Biotechnolgy
NAUT
$113M
| $1.77M | ﹤0.01% |
287,649
+249,548
| +655% | +$1.99M |
|
Similar funds
Israel Englander's Q3 2021 Portfolio in Review
As of Q3 2021, Israel Englander held 7,698 positions worth $167B, up 2.3% from $163B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Israel Englander's Q3 2021 filing shows 1,245 new, 2,719 increased, 2,446 reduced and 981 closed positions. Its largest new stake was Sight Sciences: 1,577,092 shares worth $35.8M. The largest sale was Alexion Pharmaceuticals, an estimated $887M.
By sector, the portfolio is most concentrated in Miscellaneous at 58% of assets, up from 55% a quarter earlier, followed by Technology and Financials.
- Israel Englander's largest Q3 2021 buy was Sight Sciences: 1,577,092 shares worth $35.8M.
- Israel Englander added most to State Street SPDR S&P 500 ETF Trust in Q3 2021, an estimated $643M increase.
- Israel Englander's biggest Q3 2021 reduction was Apple, cutting an estimated $694M.
- Israel Englander fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $887M.
- Israel Englander's ten largest holdings make up 18% of its $167B portfolio in Q3 2021.
- Israel Englander opened 1,245 new positions and closed 981 in Q3 2021.
- Israel Englander's portfolio value rose 2.3% quarter-over-quarter to $167B.
Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.